Account
Inquiry
Amble Tirzepatide (CAS 2023788-19-2) is a premium quality peptide compound with demonstrated efficacy in glucose control and weight management applications. This dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist represents a significant advancement in metabolic research.
The molecular structure of Amble Tirzepatide (C225H348N48O68) features PEG modification that enhances water solubility while maintaining biological activity. Clinical studies indicate superior performance compared to single-agonist compounds, with phase 3 trials demonstrating average weight reduction of 15-20.9% across different dosage regimens.
Our pharmaceutical-grade Amble Tirzepatide is supplied as a white powder in sealed vials (10mg/vial configuration) with minimum 99.9% purity. The product undergoes rigorous quality control testing to ensure batch-to-batch consistency for research applications.
As a dual agonist, Amble Tirzepatide mimics natural GIP action while simultaneously activating GLP-1 receptors. This unique mechanism has shown particular promise in type 2 diabetes management research, with additional applications in obesity-related metabolic studies.
Important Note: This product is intended for research purposes only. Not for human consumption or diagnostic use. Proper storage conditions (cool, dry environment protected from light) are essential to maintain product integrity.
